CMT-3. CollaGenex.

作者信息

Fingleton Barbara

机构信息

Vanderbilt University Medical Center, Department of Cancer Biology, 736 Preston Research Building, 23rd and Pierce Avenues, Nashville, TN 37232-6840, USA.

出版信息

Curr Opin Investig Drugs. 2003 Dec;4(12):1460-7.

PMID:14763133

Abstract

CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.

摘要